Camostat, an inhibitor of prostasin, a trypsin-like serine protease involved in activation of ENaC, is being investigated as an experimental drug in CF patients to inhibit sodium transport in the nose, restore hydration of the airway mucus and then contrast the pathophysiological cascade in this deadly disease [48]. Here, PRSS8 is linked to cystic fibrosis.